Pharmacokinetics Analysis Service

Pharmacokinetics analysis is the study of how drugs are absorbed, distributed, metabolized, and excreted (ADME) within the body. It provides essential insights into the behavior of drugs in different biological environments, helping to predict how a drug will act over time. Understanding these processes is crucial in determining the appropriate dosage, timing, and administration method for a drug, ensuring both its efficacy and safety. Pharmacokinetics analysis is particularly important during drug development and clinical trials, where it informs decisions about how a drug should be dosed and administered to achieve optimal therapeutic outcomes. Pharmacokinetics analysis relies on advanced technologies such as high-performance liquid chromatography-mass spectrometry (LC-MS/MS) and modeling techniques like physiologically-based pharmacokinetic (PBPK) modeling to collect and analyze data. These methods provide precise measurements of drug concentrations in various biological samples, enabling accurate predictions of drug behavior under different conditions. Pharmacokinetics analysis can address several critical challenges in drug development, such as optimizing drug formulations to improve bioavailability, minimizing the risk of side effects, and tailoring drug regimens for specific patient populations. Additionally, it helps identify potential drug-drug interactions and informs the safety profile of a drug. By providing a clear understanding of drug disposition and clearance, pharmacokinetics analysis is an indispensable tool in ensuring the safe and effective use of pharmaceuticals, ultimately improving treatment outcomes and reducing the likelihood of adverse effects.

 



Abdifetah, O. et al. Int J Nanomedicine. 2019.

Figure 1. Schematic Diagram of the Four Pharmacokinetic Processes: Absorption, Distribution, Metabolism and Excretion (ADME)

 

Service at MtoZ Biolabs

MtoZ Biolabs specializes in pharmacokinetics analysis service utilizing advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology and physiologically based pharmacokinetic (PBPK) modeling to provide precise data on drug absorption, distribution, metabolism, and excretion processes. We help clients optimize drug dosing, enhance bioavailability, and reduce potential toxicity through detailed pharmacokinetic analysis, thereby improving the efficiency and safety of drug development. If you are interested in our service, please feel free to contact us.

 

Service Advantages

1. Advanced Physiologically-Based Pharmacokinetic Modeling  

MtoZ Biolabs integrates PBPK modeling technology to provide accurate predictions of drug distribution, metabolism, and excretion processes within the body. Our pharmacokinetics analysis service allows for more precise simulation of drug responses in different populations (such as neonates, the elderly, etc.), thereby offering strong support for personalized drug dosage adjustment and optimization.

 

2. Advanced Pharmacokinetic Data Collection and Analysis Technology  

Utilizing high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology, MtoZ Biolabs provides high-precision pharmacokinetic data for understanding the behavior of drugs in the body, optimizing drug dosage, and addressing issues related to insufficient therapeutic efficacy and toxicity.

 

3. Cross-Disciplinary Approaches and Multi-Platform Data Integration  

MtoZ Biolabs employs cross-disciplinary approaches, combining physiology, pharmacology, and clinical data, and integrates multi-platform data analysis through PBPK modeling. This comprehensive analysis effectively addresses challenges encountered during drug delivery, such as individual differences, drug interactions, and treatment failure, thereby improving drug development efficiency and success rates.

 

Case Study

1. Comparison of Pharmacokinetics, Biodistribution, and Excretion of Free and Bound Nε-Carboxymethyllysine in Rats by HPLC–MS/MS

Nε-carboxymethyl lysine (CML), as a representative product of advanced glycation end products, exists in both free and bound forms in the body and in food, with varying bioavailability. To better understand the bioavailability of free CML and BSA-CML (bovine serum albumin-CML) after oral administration, the pharmacokinetics, biodistribution, and excretion of CML in rats were investigated using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The pharmacokinetics analysis showed that after oral administration of free CML and BSA-CML, the peak concentration of free CML in serum was reached at 1.83 h (1684.72 ± 78.08 ng/mL) and BSA-CML at 1.33 h (1440.84 ± 72.48 ng/mL), indicating that the absorption of free CML was higher than that of BSA-CML. Furthermore, based on the apparent volume of distribution and clearance rate, the body clearance and tissue distribution of dietary free CML were relatively low. Free CML also accumulated in the kidneys, suggesting that the kidneys are the target organ for the absorption of free CML. Additionally, after oral administration of free CML and BSA-CML, the total excretion rates of CML in urine and feces were 37% and 60%, respectively. These results provide key insights into the biological effects of free and bound CML on health.

 



Yuan, X. et al. Food Res Int. 2023.

Figure 2. In Vivo Biodistribution Studies of Free Nε-carboxymethyllysine in Rats at 0.5, 2, 3, and 7 h After Intragastric Administration of Free Nε-carboxymethyllysine

 

2. Quantitative Analysis, Pharmacokinetics and Metabolomics Study for the Comprehensive Characterization of the Salt-Processing Mechanism of Psoraleae Fructus

Quantitative analysis, pharmacokinetics, and metabolomics were used to explore the pharmacological effects of salt-processed Psoralea corylifolia (SPF) extract. Quantitative analysis showed that the active ingredient content in SPF extract was higher than that in the PF extract. Pharmacokinetics analysis indicated that the SPF group had higher overall AUC and tmax levels, while the Cmax was lower. Metabolomics studies revealed that PF and SPF had different effects on 22 common biomarkers and their related metabolic pathways, suggesting that salt processing can enhance the effects of PF while reducing the toxicity to the cardiovascular and renal systems. The inherent correlations between these results, along with the effects of salt processing, indicate that the heating process and the newly formed surfactants during salt processing are the main factors responsible for the changes in chemical composition and absorption characteristics, leading to enhanced efficacy and reduced toxicity.

 



Li, K. et al. Sci Rep. 2019.

Figure 2. Pharmacokinetic Parameters of Analytes in Rat Plasma

 

FAQ

Q1: How can pharmacokinetics analysis be used to optimize drug dosing regimens to improve drug bioavailability and reduce adverse effects, especially in different populations such as the elderly, children, or patients with liver and kidney dysfunction?

Answer: Optimizing drug dosing regimens to improve bioavailability and reduce adverse effects primarily relies on pharmacokinetics analysis. By studying the drug’s absorption, distribution, metabolism, and excretion (ADME) processes, the optimal dose and administration regimen can be determined. Different populations (such as the elderly, children, or those with liver or kidney impairment) may respond differently to drugs due to physiological differences, requiring personalized dose adjustments. For example, the metabolic rate in elderly individuals is often slower, so doses may need to be reduced or dosing intervals extended. Pharmacokinetic analysis also helps identify drug-drug interactions and potential toxicity, ensuring the drug’s safe and effective use in specific populations. PBPK modeling can more precisely simulate drug responses in different populations, thus optimizing treatment regimens.

 

Deliverables

1. Comprehensive Experimental Details

2. Materials, Instruments, and Methods

3. Relevant Liquid Chromatography and Mass Spectrometry Parameters

4. The Detailed Information of Pharmacokinetics

5. Mass Spectrometry Image

6. Raw Data